Merck expands portfolio of liquid biopsy t...Merck KGaA has expanded its portfolio of blood-based RAS diagnostics for use in patient stratification. After kicking off testing with Sysmex Inostics’ CE-marked OncoBEAM RAS CRC liquid biopsy … more ➔
TiGenix launches IPO in the USEuronext Brussels-noted adipose stem cell player TiGenix NV wants to offer 2.75 million American Depositary Shares (ADS) in an IPO at Nasdaq Global Market representing 55 million of its ordinary shares … more ➔
Roche licenses Novimmunes anti-TLR4 anti...Roches US subsidiary Genentech has acquired an exclusive option to commercialise Novimmune’s TLR4 antibody NI-0101, the very first personalised approach to treat rheumatoid arthritis. The compound … more ➔
Mediolanum licences Apepticos TNF peptid... Viennese Apeptico Forschung und Entwicklung GmbH and Milan-based Mediolanum Farmaceutici S.p.A. have signed a research & development cooperation and license agreement for Apepticos compound s … more ➔
A fresh take on biotech?For the second time, biotech communication start-up Labiotech hosted its event LBRefresh, this year in Paris, France. Participants enjoyed panel discussions, a start-up battle and intimate fireside chats… more ➔
Bioplastics industry grapples with ignoran...EU consumers have minor knowledge on bioplastics but unrealistically high expectations that can not be fulfilled, researchers said at 11th European Bioplastics Conference in Berlin. more ➔
Carbios tackles marine litteringFrench Carbios has presented a process that depolymerises one of the most common non-recycled plastics polluting the oceans. more ➔
Neovacs teams up with 3PFrench immunotherapy expert Neovacs has teamed up with CDMO 3P Biopharmaceuticals for the manufacture of interferon alpha with recently licensed technology. more ➔
Kymab raises €94m for mAb pipelineUK-based biopharma group Kymab has brought a new backer from China on board. With the help from ORI Healthcare Fund, Kymab secured a US$100m Series C financing. more ➔
Proteros inks US$167m oncology pact with M...Proteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncolog … more ➔
